Introduction {#s1}
============

Hepatic Encephalopathy (HE) is a series of neuropsychological abnormalities secondary to liver dysfunction after excluding other known brain diseases, such as behavioral, intellectual and cognitive changes ([@B11]). Acute liver failure (ALF) is also called fulminant hepatic failure (FHF), which refers to various causes leading to severe acute liver injury, thus causing some potential and reversible diseases such as electrolyte metabolic disorder, jaundice, HE, etc ([@B41]). Although the diseases are potentially reversible, they are all based on the loss of the detoxification function of the liver. The increase of toxins affects various systems in the body, and the mortality rate is high ([@B5]). One of the main components of ALF is the development of brain edema, which leads to increased intracranial pressure and brain herniation, eventually leading to death ([@B1]). The disease is also called AHE.

Evidence shows that brain edema in AHE is due to edema of astrocytes ([@B39]; [@B40]; [@B3]; [@B33]). An elevated ammonia level always exists in HE patients ([@B16]). The occurrence of astrocyte edema seems to be affected by ammonia toxicity ([@B13]; [@B14]; [@B37]). Astrocytes mainly convert glutamic acid into glutamine through ammonia detoxification reaction, mediated by glutamine synthetase ([@B27]). The dysfunction of astrocytes caused by ammonia-induced oxidative stress is also the core of AHE ([@B29]). GFAP is a landmark structural protein of astrocytes and participates in cell volume regulation. AQP4 specifically expresses on the capillary side of the protuberant foot plate of brain astrocytes and regulates the transmembrane flow of water. The changes in their expression are involved in astrocyte edema ([@B31]).

NRF2 is a major regulator in the redox balance ([@B4]). In normal conditions, NRF2 combines with Kelch-like ECH-associated protein1 (KEAP1) in an activity inhibition state ([@B38]). Under the action of the oxidative stress, NRF2 releases from KEAP1 and combines with the antioxidant response element (ARE) in the nucleus, then activates antioxidant enzyme genes expression such as heme oxygenase 1 (HO-1), NADPH quinine oxidoreductase 1 (NQO1), and GSH synthesis (GCLM, GCLC) ([@B22]; [@B25]). HO-1 is one of the most extensive antioxidant defense enzymes and a member of the heat shock protein family. It has anti-inflammatory, antioxidant, anti-apoptosis, and anti-proliferative effects. NQO1 is a flavin enzyme, which plays a key role in collective detoxification metabolism. GCLM and GCLC form glutamic acid cysteine ligase, which are two important genes in cell antioxidant defense mechanisms and play an important role in regulating glutathione synthesis. When cells are damaged by oxidative stress, gene expressions are up-regulated, glutathione synthesis is increased, and oxidative defense mechanism is enhanced ([@B24]; [@B34]). It was found that NRF2 regulated the activity of the antioxidant enzymes and the expression of down-stream genes to protect against brain edema ([@B45]; [@B7]; [@B8]). However, whether NRF2 plays a regulatory role in the occurrence and development of AHE needed further research and confirmation.

Xiaochaihutang (XCHT, Sho-Saiko-to, SST in Japan) is a classic formula of traditional Chinese medicine, which is first recorded in 'Shang Han Lun' and has the effects of anti-inflammation, hepatic protection, antipyretic and analgesic treatment. Our previous research found that XCHT can reduce liver cell necrosis and enhance liver function by activating the NRF2 pathway, thus playing a role in protecting the liver ([@B23]; [@B17]; [@B20]). Moreover, studies have shown that XCHT can play a role in neurological diseases, such as the treatment of depression ([@B35]), etc. However, whether XCHT treats brain edema through the NRF2 pathway in AHE rats remains to be clarified.

Therefore, this study aimed to investigate the pharmacological effects of XCHT on AHE rats, and subsequently delineated the underlying mechanisms which might be involved in it.

Materials and Methods {#s2}
=====================

Animals, Drugs, and Treatments {#s2_1}
------------------------------

Male Sprague-Dawley rats weighing 180-220 g (Experimental Animal Centre of the Third Military Medical University) were used for the experiments. Animals were fed in a room with a 12-h light/dark cycle at constant humidity and temperature (22-25°C) and had chow and water ad libitum placed in the cages. Animal maintenance and experimental protocols were carried out in accordance with guidelines approved by the Care Committee of Zunyi Medical University and the NIH guide of Humane Use.

Xiaochaihutang is a traditional Chinese Medicine. Xiaochaihu granule (containing Bupleurum falcatum L. (1.5 g), Scutellaria baicalensis Georgi (0.56 g), Codonopsis pilosula Franch (0.56 g), Pinellia temata Breitenbach (0.56 g), Glycyrrhiza glabra L.(0.56 g), Zingiber officinale Roscoe (0.56 g), and Zizyphus vulgaris Lam. (0.56 g)), referring to the ancient method of decocting, was purchased from Baiyunshan Guanghua Pharmaceutical Co., Ltd. (approval number K70079, Guangzhou, China). According to the 2015 edition of the Pharmacopeia Committee of China ([@B32]), baicalin is used as the index of Xiaochaihu granule, and the content of baicalin in Xiaochaihu granule, measured by high performance liquid chromatography (HPLC) in our previous studies, is 24.307 mg/10g. This conforms to the requirement of not less than 20 mg/10g.

After acclimatization for one week, rats were randomly divided into five groups (50, n = 10): vehicle group, model group, XCHT treatment groups (the instruction of Xiaochaihu granule suggests that patients should take 6-12 g/day, and considering the dose conversion from human to rats, the dose of XCHT is clinically relevant: 1.0 g/kg, 2.0 g/kg, 4.0 g/kg). To induce acute hepatic encephalopathy, rats in model and XCHT groups were given TAA (300 mg/kg/day, i.p.) for three consecutive days ([@B19]). Starting from the 4^th^ day, the animals in treatment groups were given the appropriate doses of XCHT granules for 2 weeks (1 mL/100 g/day, i.g.). In the end after 2 weeks of treatment, the mortality rate of rats was about 10%. Then behavior was tested and all rats were sacrificed to obtain blood and cerebral cortex samples.

Observation and Measurement of Rat Behaviors {#s2_2}
--------------------------------------------

Rats were observed after administrations and recorded in an open field. Behaviors included mortality, body weight and auto-activity. All studies were performed under strictly standardized conditions in a dark room for 10 min. The total distances were recorded to reflect the auto-activities of rats with AHE. The activities were defined as zero in dead rats ([@B42]).

Brain Water Measurement {#s2_3}
-----------------------

Brain water content was evaluated as previously described ([@B9]). The cerebral cortex was removed and separated into 2 parts. The left hemisphere was weighed for wet weight. Tissue dried for 72 h in an oven at 110°C, and dry weights were determined. The percentage of water content was calculated as \[(wet weight − dry weight)/wet weight\] × 100%.

Biochemical Analysis {#s2_4}
--------------------

The plasma was separated and the blood ammonia level was detected according to the instructions of the kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The cortex was isolated from the brain of rat. After homogenizing the cortex, the levels of GS, MDA and T-SOD were determined according to the instructions of the kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Protein concentrations were determined using the Bradford method.

IHC of GFAP in AHE {#s2_5}
------------------

IHC for GFAP was carried out on cerebral cortex tissue slices after deparaffinization, rehydration, antigen unmasking by heat treatment, and 5% normal goat serum blocking. Slices were incubated with a specific primary antibody overnight at 4 °C, then processed using a GTVision kit (Gene Tech, Shanghai, China) according to the technical manual. Five areas of each slice were randomly examined under an optical microscope (OLYMPUS, BX5, Japan).

Astrocyte Cultures {#s2_6}
------------------

Primary cultures of cortical astrocytes were prepared as described previously ([@B15]). Primary cultures of cortical astrocytes were prepared from 1/2-day-old rats. Briefly, the cerebral cortex was stripped from the meninges, minced and dissociated by trituration, passed through sterile nylon sieves and then placed in Dulbecco\'s modified Eagle medium (DMEM) containing 10% FBS. The medium was changed after 24 h. Astrocytes were incubated at 37 °C in a humidified chamber provided with 5% CO~2~ and 95% air. Cultures consisted of at least 95% astrocytes and were determined by GFAP IF.

There were three groups: 10% (v/v) control-serum group (vehicle group), 10% (v/v) control-serum and NH~4~Cl (5 nM) group (model group), and 10% (v/v) XCHT compound serum and NH~4~Cl (5 nM) group (XCHT group). Serums were provided by preliminary work of our group ([@B17]). In brief, 30 rats were randomly divided into two equal groups, which includes the control (vehicle) group (n=15) and XCHT treatment group (n=15). The XCHT group received an oral administration of 2 g/kg decoction for 6 days (considering the dose conversion from human to rat, the dose of XCHT was clinically relevant; according to the results of previous in vivo experiments, we chose 2.0 g/kg for administration). A distilled water vehicle control was given to the control group. Then the blood samples were obtained from the abdominal aorta 2 h after oral administration and centrifuged at 3500 rpm for 15 min. The serum samples were mixed and inactivated.

IF Microscopy {#s2_7}
-------------

Astrocytes were cultured on glass coverslips for 24 h and treated for a further 24 h. Coverslips were washed with PBS, fixed in 4% (v/v) paraformaldehyde for 20 min at room temperature, washed prior to detergent extraction with 0.5% (v/v) Triton X-100 for 20 min., then saturated with PBS containing 5% (v/v) normal goat serum for 30 min. Next, cells were incubated with the specific primary antibody for AQP4 over-night, washed, then incubated with secondary antibody for 1 h at 37 °C. Finally, cells were stained for 5 min with 4,6-diamidino-2-phenylindole (DAPI). OLYMPUS IX73 microscope was used to observe the slides.

Real Time PCR Analysis {#s2_8}
----------------------

Total RNA was extracted from cerebral cortex tissues and treated cortical astrocytes using RNAiso plus (TAKARA, Dalian, China). The primers were designed and synthesized by TAKARA Systems. The sequences of the primers were listed in [**Table 1**](#T1){ref-type="table"}. The total RNA was reverse-transcribed with 5 × PrimeScripe TM Buffer, Prime Script TMRT Enzyme Mix, and Oligo dT Primer. The SYBR green PCR Master Mix was chosen for real time PCR analysis. A relative quantitative method was used for analysis of results.

###### 

The primer sequence for RT-PCR.

  Gene      Sequence (5′\~3′)          
  --------- -------------------------- ---------------------------
  β-actin   GGAGATTACTGCCCTGGCTCCTA    GACTCATCGTACTCCTGCTTGCTG
  NRF2      TTGGCAGAGACATTCCCATTTGTA   GAGCTATCGAGTGACTGAGCCTGA
  KEAP1     CATCGGCATCGCCAACTTC        GCTGGCAGTGTGACAGGTTGA
  HO-1      AGGTGCACATCCGTGCAGAG       CTTCCAGGGCCGTATAGATATGGTA
  NQO1      TGGAAGCTGCAGACCTGGTG       CCCTTGTCATACATGGTGiGCATAC
  GCLC      CTGCACATCTACCACGCAGTCA     ATCGCCGCCATTCAGTAACAA
  GCLM      AGACCGGGAACCTGCTCAAC       GATTTGGGAGCTCCATTCATTCA
  GFAP      TCGTGTGGATCTGGAGAGGAAGG    AGAGCCGCTGTGAGGTCTGG
  AQP4      GAAGGCGGTCACAGCAGAGTTC     TGATGTGGCCGAAGCACTGAAC

Western Blot Analysis {#s2_9}
---------------------

Cytoplasmic and nuclear protein of cerebral cortex tissues and treated cortical astrocytes were extracted by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo-Scientific, Rockford, United States). Equal amounts of protein (15 μg) were separated on 10% SDS-polyacrylamide gel. The blots were incubated overnight with individual protein anti-bodies (1:1000, Abcam, Cambridge, UK), washed, incubated with anti-rabbit IgG, anti-mouse IgG (1:5000, ZSGB-BIO, Beijing, China) for 2 h, and developed by ECL western blotting substrate. Western blot signals were quantified by Imager (Bio-Rad, America).

Statistical Analysis {#s2_10}
--------------------

All data were expressed as mean ± standard deviation (S.D). Statistical analysis was performed with Student's *t* test and ANOVA with the Tukey post hoc test was used if more than two experimental groups were compared, and *p* \< 0.05 was considered statistically significant. Data were analyzed with GraphPad Prism 5.0 (La Jolla, CA, USA).

Results {#s3}
=======

XCHT Treatment Suppressed the Development of TAA-Induced AHE {#s3_1}
------------------------------------------------------------

To analyze the effect of XCHT on TAA-induced AHE in rats, the degree of liver injury in the rats was at first measured ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). Subsequently the behaviors \[scoring ([**Figure 1A**](#f1){ref-type="fig"}), total distance traveled ([**Figure 1B**](#f1){ref-type="fig"})\], the brain cortical water content ([**Figure 1C**](#f1){ref-type="fig"}), the ammonia plasma ([**Figure 2A**](#f2){ref-type="fig"}), and the GS ([**Figure 2B**](#f2){ref-type="fig"}) levels in all groups of rats were measured. Compared with the vehicle group, significant changes in behavior, decreased auto-action, increased brain water content, blood ammonia and GS in the cerebral cortex were observed in the TAA group relative to the vehicle group. Whereas in rats treated with XCHT behavior scoring improved during the first week, and increased automatic action, decreased brain water content, blood ammonia, and GS were observed. Together, the data presented here demonstrated that XCHT enabled the healing of TAA-induced AHE.

![Acute hepatic encephalopathy (AHE) was induces by repeated injection of 300 mg/kg/day thioacetamide (TAA) for 3 days (1 mL/kg in saline, i.p.). From the 4th day, the animals in treatment groups were given the XCHT granules (1.0 g/kg, 2.0 g/kg and 4.0 g/kg, 1mL/100 g/day, i.g.) for 2 weeks. **(A, B)** Measurement of the rat behaviors \[**(A)** Animal behavior scoring. **(B)** Open field test. Rats in each group were evaluated for total distance traveled\]. **(C)** Brain water content (\[(wet weight -- dry weight)/wet weight\] × 100%). Data were expressed as mean ± SD (n = 5-7). ^\#^*p* \< 0.05, ^\#\#^*p*\< 0.01 vs. the vehicle group. \**p* \< 0.05, \*\**p* \< 0.01 vs. the TAA group.](fphar-11-00382-g001){#f1}

![Effect of XCHT on ammonia level in TAA induced AHE rats. **(A)** Ammonia plasma levels in all groups of rats. **(B)** GS levels in cerebral cortex of rats. Data were expressed as mean ± SD (n = 5-7). ^\#^p \< 0.05, ^\#\#^p \< 0.01 vs. the vehicle group. \*p \< 0.05, \*\*p \< 0.01 vs. the TAA group.](fphar-11-00382-g002){#f2}

XCHT Reduced the Degree of TAA-induced Oxidative Damage in AHE Rats {#s3_2}
-------------------------------------------------------------------

In order to detect the oxidative damage degree of AHE rat, we measured the levels of MDA ([**Figure 3A**](#f3){ref-type="fig"}) and T-SOD ([**Figure 3B**](#f3){ref-type="fig"}) in the cerebral cortex by colorimetry. Compared with the vehicle group, MDA level was found to be dramatically increased in the TAA group, and in contrast the level of T-SOD was obviously decreased. However, the groups of XCHT treatment noticeably prevented oxidative stress production in a dose-dependent manner. The data presented here demonstrated that XCHT enabled the healing of TAA-induced AHE by reducing oxidative stress damage.

![Effects of different doses of XCHT on oxidative stress level \[MDA **(A)** and T-SOD **(B)**\] in cerebral cortex of TAA induced AHE rats. Data were expressed as mean ± SD (n = 5-7). ^\#\#^p \< 0.01 vs. the vehicle group. \*p \< 0.05, \*\*p \< 0.01 vs. the TAA group.](fphar-11-00382-g003){#f3}

XCHT Activated NRF2 Pathway in AHE Rats {#s3_3}
---------------------------------------

To examine whether different doses of XCHT inhibit the destruction of cortical astrocytes in an experimental model of AHE (TAA treated rats), cortical sections from each group (n=3) were immunostained with GFAP, and images were captured with a microscope. Faint GFAP staining of astrocytes were observed in the TAA group. However, intense GFAP IHC was found in XCHT treatment groups ([**Figure 4**](#f4){ref-type="fig"}). In order to determine whether XCHT could protect the cerebral cortex by activating the NRF2 pathway, the expression of NRF2 pathway proteins and genes (Nucl-NRF2 ([**Figure 5B**](#f5){ref-type="fig"}), Cyto-NRF2, KEAP1, HO-1, NQO1, GCLC, GCLM) ([**Figures 5A, C**](#f5){ref-type="fig"}) were further quantified in each group by western blots and real time PCR. Compared with the vehicle group, the TAA group showed a decrease in Nucl-NRF2 and proteins on the NRF2 pathway. In contrast, XCHT treatment groups showed an increase in Nucl-NRF2 and proteins on the NRF2 pathway. At the same time, the level of GFAP and AQP4 in the cerebral cortex was detected and compared with the model group. The expression of GFAP in the XCHT treatment group was increased while there was a decrease in AQP4 protein ([**Figures 5A, C**](#f5){ref-type="fig"}). These results indicated that XCHT might activate the NRF2 pathway to improve brain edema induced by AHE in rats.

![Effect of XCHT on structure of the astrocytes in cerebral cortex of AHE rats. GFAP expression in cerebral cortex of rat brain (IHC, 200×). The decrease of GFAP immunostaining in cortex of TAA group rats compared to the vehicle group, which indicated that the structure of astrocytes was destroyed and brain edema occurred. In contrast, the expression of GFAP in astrocytes increased in the treatment groups with different doses.](fphar-11-00382-g004){#f4}

![Effect of XCHT on TAA-induced AHE in rats by activating cortical astrocytes NRF2 pathway. **(A)** The mRNA expression of NRF2, KEAP-1, HO-1, NQO-1, GCLC, GCLM, GFAP and AQP4. **(B)** The protein expression of Nucl-NRF2. **(C, D)** The protein expression of Cyto-NRF2, KEAP-1, HO-1, NQO-1, GCLC, GCLM, GFAP and AQP4. Data were expressed as mean ± SD (n = 5-7). ^\#^p \< 0.05, \*p \< 0.01 vs. the TAA group.](fphar-11-00382-g005){#f5}

Effect of XCHT Compound Serum on the Ammonia-Induced Cell Edema in Astrocytes {#s3_4}
-----------------------------------------------------------------------------

The obtained astrocyte culture purity and maturity was put under immunocytochemical examination using an antibody against to the GFAP protein. The astrocyte purity was greater than 95% for the following experiments ([**Figure 6A**](#f6){ref-type="fig"}).

![Effect of XCHT compound serum on ammonia-induced astrocyte swelling. **(A)** Purity of primary astrocyte culture. Immunolabeling of primary rat astrocyte cultures with the markers GFAP (Red) revealed pure primary astrocyte culture. Nucleus were stained with 4′,6′-diamidino-2-phenylindole (DAPI) (Blue). (Staining, 100×) **(B)** Morphological overview of astrocyte culture after treatment. **(C)** Immunolabeling of primary rat astrocyte cultures with the markers AQP4 (Green), Nucleus were stained with 4′,6′-diamidino-2-phenylindole (DAPI) (Blue).](fphar-11-00382-g006){#f6}

Since XCHT has a protective effect on the liver and reduces the ammonia level in the body, whether or not XCHT has a direct therapeutic effect on cerebral edema caused by AHE needs to be further determined. Cultures were divided between the vehicle group (10% control-serum), the model group (5 mM NH~4~Cl and 10% control-serum) and the XCHT group (5 mM NH~4~Cl and 10% XCHT compound serum). After 24 h treatment, the cell morphology was observed by a microscope. An increased tense had been seen in cell volume and the cell refractive index was observed after exposure to ammonia for 24 h. Such edema was attenuated by treatment of cells with XCHT compound serum ([**Figure 6B**](#f6){ref-type="fig"}). Compared with the vehicle group, intense AQP4 IF cortical astrocytes were found in the model group. But faint AQP4 staining of astrocytes were observed in the XCHT group ([**Figure 6C**](#f6){ref-type="fig"}).

Discussion {#s4}
==========

In our present study, we investigated whether XCHT has a potentially protective effect on brain edema associated with AHE, which works by activating the NRF2 pathway. To clarify the effect of XCHT on brain edema caused by AHE, we performed in vivo and vitro experiments respectively and detected the expression of GFAP, AQP4 involved in astrocyte edema as well as the NRF2 pathway (Nucl-NRF2, Cyto-NRF2, HO-1, NQO-1, GCLC and GCLM). This study demonstrates for the first time that the occurrence of AHE-related brain edema may be associated with the NRF2 pathway, and that XCHT, by offering a protective role against ammonia-induced brain/astrocyte edema through activating the NRF2 pathway, may be a promising candidate for AHE treatment.

As mentioned earlier, studies demonstrated that the occurrence of brain edema caused by AHE was related to oxidative stress ([@B2]; [@B28]). Since it is the central regulator of cell antioxidant response, the NRF2 pathway plays an important role in the mechanism of cell resistance to internal and external oxidative stress. Studies elaborated that the NRF2 pathway was involved in brain edema caused by various factors ([@B44]; [@B12]; [@B21]). Although some studies analyzed that AHE-induced astrocyte edema was related to the downstream gene HO-1 of the NRF2 pathway ([@B30]), there is no evidence that it is directly related to NRF2 pathway. Therefore, we assumed that the occurrence of brain edema caused by AHE may be related to the NRF2 pathway. In vivo and vitro, the results showed that ammonia inhibited and reduced the activation of the NRF2 pathway in astrocytes, thus leading to the occurrence of brain edema ([**Figures 4**](#f4){ref-type="fig"}, [**6**](#f6){ref-type="fig"}), which is consistent with our hypothesis.

XCHT plays a protective role in disease models damaged by oxidative stress. Our previous studies proved that XCHT could reduce the related symptoms of liver fibrosis and ALF in rats by activating the NRF2 pathway ([@B20]). Wang et al. proved that XCHT could protect human skin fibroblasts from oxidative stress injury induced by hydrogen peroxide through blocking NF-κB ([@B43]). At present, studies showed that XCHT could be able to treat neurological related diseases, such as depression ([@B26]). Therefore, we assumed that XCHT could also activate the NRF2 pathway in the brain after AHE, and reduce the occurrence of brain edema by inhibiting oxidative stress. For this reason, XCHT was given to treat AHE rats in this study. The results showed that XCHT activated the NRF2 pathway and promoted NRF2 translocation from cytoplasm to the nucleus. This translocation alleviates the symptoms of brain edema caused by oxidative stress injury and also alleviates the occurrence of AHE. However, the effect of XCHT treatment with 1.0 or 4.0 mg/kg on rats was not as good as that with 2.0 mg/kg ([**Figure 5**](#f5){ref-type="fig"}). Although the cause of this effect is not clear, low or high concentrations of XCHT may produce non-specific effects.

Previously, it was proved that administration of XCHT to ALF rats could improve liver oxidative damage through the NRF2 pathway, which indicated that XCHT had beneficial effects on ALF ([@B20]). As XCHT is reported to have a hepato-protective effect, the beneficial effect of XCHT on AHE-induced brain edema observed in this study might be because of the secondary one liver function improvement. And we further verified this conjecture.

In order to simulate the environment in vivo, we selected 10% XCHT compound serum to treat astrocytes in ammonia environment according to previous studies. Studies found that XCHT compound serum contained a variety of active ingredients (such as liquiritin, rutin, zingerone, baicalin, quercetin, etc.) ([@B36]; [@B6]). We also detected baicalin in the serum used in this study ([**Supplementary Figure 2**](#SM1){ref-type="supplementary-material"}), and previous studies found that liquiritin, rutin, baicalin and other components could enter the brain through the blood-brain barrier (BBB) ([@B18]; [@B6]; [@B10]). These results showed that XCHT compound serum could protect the structure of astrocytes and reduce AQP4 expression in cells. These results were consistent with our previous work in vitro. All the results proved that the recovery from the brain edema in TAA-induced AHE rats after treatment with XCHT might be due to a direct effect of XCHT on brain edema and a direct effect of improvement in liver function.

However, the study had several limitations. Firstly, since XCHT is a compound Chinese Medicine, which has multitarget features and a variety of protective effects such as antioxidative and anti-inflammatory properties ([@B17]), we should consider if its protection in AHE is related to its anti-inflammation or other properties in our study. Secondly, in order to simulate the internal environment, we should choose drug-containing cerebrospinal fluid for the cell part. However, considering the small amount of cerebrospinal fluid in rats and the large amount needed in the experimental process, we chose drug-containing serum for this study. Although it was proven that baicalin produced after XCHT entering the body for metabolism could enter the brain, the effect of serum on astrocytes may cause slight deviation in the experimental results. Thirdly, our experiment treated XCHT only at the beginning of AHE. The therapeutic effect of XCHT on AHE in different clinical stages needed further study.

In summary, NRF2 pathway protein and mRNA levels were decreased in the cerebral cortex in the TAA model of AHE rats, but treatment with XCHT reduced the brain edema as well as improved their clinical status. Decreased NRF2 was associated with brain edema and activating this pathway with XCHT significantly reduced the edema. Astrocytes treated with ammonia showed the same change in AQP4 as the TAA model of AHE. Our findings suggest that the NRF2 pathway is related to brain/astrocyte edema in AHE, and XCHT might be an effective method for the treatment of brain edema associated with AHE.
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